<scp>DUAL</scp> I China: Improved glycemic control with <scp>IDegLira</scp> versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs-Reference-Cited by-同舟云学术

DUAL I China: Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs

Published:2022-06 Issue:6 Volume:14 Page:401-413
ISSN:1753-0393
Container-title:Journal of Diabetes
language:en
Short-container-title:Journal of Diabetes

Author:

Wang Weiqing¹,Agner Bue F. Ross²,Luo Bin³,Liu Lei⁴,Liu Ming⁵,Peng Yongde⁶,Qu Shen⁷,Stachlewska Karolina Amelia⁴,Wang Guixia⁸,Yuan Guoyue⁹,Zhang Qiu¹⁰,Ning Guang¹^ORCID

Affiliation:

1. Department of Endocrine and Metabolic Diseases, Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China

2. Bispebjerg Hospital Copenhagen Denmark

3. Novo Nordisk China Pharmaceuticals Beijing China

4. Novo Nordisk A/S Søborg Denmark

5. Department of Endocrinology and Metabolism Tianjin Medical University General Hospital Tianjin China

6. Department of Endocrinology and Metabolism, Shanghai General Hospital Shanghai Jiao Tong University Shanghai China

7. Department of Endocrinology and Metabolism Shanghai Tenth People's Hospital of Tongji University Shanghai China

8. Department of Endocrinology and Metabolism The First Hospital of Jilin University Jilin China

9. Department of Endocrinology and Metabolism Affiliated Hospital of Jiangsu University Zhenjiang China

10. Department of Endocrinology and Metabolism The First Affiliated Hospital of Anhui Medical University Hefei China

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1753-0407.13286

Reference32 articles.

1. IDF.IDF Diabetes Atlas 9th Edition 2019. Accessed December2 2019.https://www.diabetesatlas.org/en/resources/

2. Standards of medical care for type 2 diabetes in China 2019;Jia W;Diabetes Metab Res Rev.,2019

3. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States

4. Blood glucose profiles in East Asian and Caucasian injection-naive patients with type 2 diabetes inadequately controlled on oral medication: a pooled analysis

5. Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Conversion of Intensive Insulin Therapy to IDegLira Demonstrates Higher Efficacy and Safety in Reducing Fasting Blood Glucose and HbA1c in T2DM Patients;Diabetes, Metabolic Syndrome and Obesity;2024-08

2. Clinical perspectives on the frequency of hypoglycemia in treat-to-target randomized controlled trials comparing basal insulin analogs in type 2 diabetes: a narrative review;BMJ Open Diabetes Research & Care;2024-05

3. Guideline for the Management of Diabetes Mellitus in the Elderly in China (2024 Edition);AGING MEDICINE;2024-02

4. Efficacy and safety of fixed‐ratio combination insulin degludec/liraglutide in type 2 diabetes: A systematic review and meta‐analysis of randomised controlled trials;Diabetes/Metabolism Research and Reviews;2023-11-27

5. IDegLira for type 2 diabetes: a systematic review and meta-analysis;Endocrine;2023-09-28